APRE - Latest News
Aprea Therapeutics, Inc. (APRE), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $10.4M. Beta to the broader market is 1.59.
The article list below shows the most recent APRE headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent APRE Headlines
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
globenewswire.com - Aug 28, 2026
Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents Company Strengthens Global Intellectual Property Port
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
globenewswire.com - Aug 12, 2026
Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances
Lipocine Appoints Michael J. Grissinger to Board of Directors
prnewswire.com - Aug 3, 2026
/PRNewswire/ -- Lipocine Inc.
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
globenewswire.com - Jul 30, 2026
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-ter
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
globenewswire.com - Jun 1, 2026
Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor typ
How News Affects APRE Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track APRE's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked APRE news questions
- What is the latest APRE news headline?
- The most recent APRE headline (Aug 28, 2026) is "Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the APRE news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What APRE news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual APRE options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.